Clinical Trials Logo

Stage I Gastric Cancer clinical trials

View clinical trials related to Stage I Gastric Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT04454476 Active, not recruiting - Gastric Cancer Clinical Trials

Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor

Start date: November 9, 2022
Phase: Phase 1
Study type: Interventional

This is a study of the safety and effectiveness of Trametinib treatment in patients who have received successful endoscopic submucosal resection of a Stage I gastric cancer.

NCT ID: NCT04394585 Recruiting - Clinical trials for Stage I Gastric Cancer

Effect of Smart Phone App-based Human Coaching Program in Gastrectomized Patients

Start date: April 20, 2020
Phase: N/A
Study type: Interventional

This study is a single center, prospective, randomized controlled study. The aim of this study is to evaluate the effect of smart phone app-based human coaching program on QOL in patients who underwent gastrectomy for stage I gastric cancer. The hypothesis of this study is the patients who used smart phone app-based human coaching program for three months after surgery will have better QOL than patients who did not use it. The QOL will be assessed using EORTC QLQ C30 and STO22 at 3 months postoperatively. The secondary endpoints are QOL at 6 months postoperatively, 12 months postoperative, food intake, body composition, and nutritional indicators from blood test.

NCT ID: NCT00087191 Terminated - Clinical trials for Fallopian Tube Cancer

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

Start date: May 2004
Phase: N/A
Study type: Interventional

This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer. EF5 may be effective in measuring oxygen in tumor tissue. Photosensitizing drugs such as motexafin lutetium are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. Knowing the level of oxygen in tumor tissue and the level of motexafin lutetium absorbed by tumors and normal tissue may help predict the effectiveness of anticancer therapy